Ipsen And Galderma Enter Exclusive Partnership In Neurotoxins
Specialty pharmaceutical company Ipsen and global healthcare firm Galderma announced that they have entered into an exclusive partnership to develop and market new neurotoxins, including their liquid formulations. The partners have also extended the scope of their distribution partnership for Dysport/Azzalure in the U.S. and Canada.
As part of the agreement, distribution rights to Dysport in aesthetic and dermatology indications in the two countries have been included in the collaboration. Dysport is Ipsen’s botulinum toxin type A used as a neuromuscular blocking toxin originally developed for the treatment of motion disorders, such as muscular spasm and cervical dystonia, among others. The renegotiated agreement for Dysport extends up to 2036 between the two companies. Galderma will pay 25 million euros to Ipsen while Ipsen will be responsible for the manufacture and supply of the neurotoxin and will receive royalties from Galderma.
The partners will also expand their R&D collaboration and will open access to each one’s research compounds. Ipsen will pay 10 million euros to gain intellectual property rights for Galderma’s liquid toxin in the U.S., Canada, EU, and Brazil. Galderma will retain its marketing rights to its product.
Ipsen CEO Marc de Garidel and Galderma International CEO Humberto C. Antunes said, “We are convinced that this agreement is beneficial to both companies, that it will create significant value for our respective shareholders, and benefit patients through existing neurotoxins and those in development.”
Earlier this year, Ipsen announced that it is ramping up the resupply of orphan drug Increlex for the treatment of growth failure in children in the U.S. in partnership with the U.S. Food and Drug Administration (FDA). The announcement comes roughly a year after Lonza Biologics, the supplier of Increlex’s main ingredient, was plagued with supply interruption issues.
Galderma reported earlier this month that it has secured full distribution rights not only to Dysport but also to Restylane, Perlane, Emervel, and Sculptra from Valeant Pharmaceuticals.